Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease

✍ Scribed by Robert A. Hauser; Mark F. Lew; Howard I. Hurtig; William G. Ondo; Joanne Wojcieszek; Cheryl J. Fitzer-Attas

• Publisher: John Wiley and Sons
• Year: 2009
• Tongue: English
• Weight: 329 KB
• Volume: 24
• Category: Article
• ISSN: 0885-3185
• DOI: 10.1002/mds.22402

✦ Synopsis

Abstract

The purpose of this study to compare the long‐term clinical outcome of early versus delayed rasagiline treatment in early Parkinson's disease (PD). Subjects (N = 404) were randomly assigned to initial treatment with rasagiline (early‐start group) or placebo for 6 months followed by rasagiline (delayed‐start group) in the TEMPO study. Subjects who chose to participate in an open‐label extension (N = 306) continued to receive rasagiline as well as other PD medications as needed. Average (±SD) duration in the study was 3.6 ± 2.1 years; 177 subjects received rasagiline for ≥5.0 years. Over the entire 6.5‐year follow‐up period, the adjusted mean difference in change from baseline in total UPDRS scores was 2.5 units (SE 1.1; P = 0.021) or 16% (SE 5.7; P = 0.006) in favor of the early‐start versus delayed‐start rasagiline group. Although the interaction between treatment and time was significant, values for the early‐start group were better than the delayed‐start group across all time points. Significantly less worsening (percent change) in total UPDRS scores was observed in the early‐start group at the time points 0.5, 1.5, 2.0, 3.0, 4.5, 5.0, and 5.5 years (P < 0.05). Compared to delayed start, early initiation of rasagiline provided long‐term clinical benefit, even in the face of treatment with other dopaminergic agents. This might reflect enduring benefits due to neuroprotection or effects on compensatory mechanisms in early PD. © 2008 Movement Disorder Society